Edit

Longwood Fund

https://www.longwoodfund.com

Last activity: 14.02.2025

Active

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.

Portfolio

Mentions

Location: United States, Massachusetts, Boston

Employees: 1-10

Founded date: 2010

Investment Type: Venture Capital

Twitter

Portfolio 1

Date	Name	Website	Total Raised	Location
24.06.2022	DEM Biopha...	dembiopharma.com	$70M	United Sta...

Mentions in press and media 21

Date	Title	Description
15.02.2025	Newleos Therapeutics: A New Dawn in Neuropsychiatric Treatment	In the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company...
14.02.2025	Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric Disorders	Newleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ...
13.02.2025	Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines	-Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions- -Multiple clinical-stage programs licensed from Roche, ready for pr...
15.01.2025	Be Bio Closes $92M Series C Financing	Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,...
09.11.2024	Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases	In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune...
08.11.2024	Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases	Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA...
28.10.2024	Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding	In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn...
25.10.2024	Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines	Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo...
03.04.2024	From generative chemistry to computational astrophysics, startups employ new methods to fight cancer	Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o...
19.03.2024	Engrail Therapeutics raises $157M Series B	Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round. Th...
05.05.2023	Longwood Fund Closes Sixth Fund, at $180M	General Partners Christoph Westphal and David Steinberg Longwood Fund, a Boston, MA-based venture capital firm dedicated to creating and investing in science-based companies, closed its sixth fund, at $180M. This fund will continue focusing...
05.01.2023	Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference	CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Bedding...
08.09.2022	Photys Therapeutics raises $75M in Series A funds to control disease-causing proteins	A new drug company emerged from stealth on Thursday. Photys Therapeutics debuted with a $75 million Series A funding round led by MPM Capital. The Boston-based company was founded last year by Longwood Fund — a venture capital firm that cre...
25.10.2020	Startup focused on B-cell therapies launched with $52M in Series A	“We have an ambitious plan to be the company that knows how to make B cells and mirror them precisely and make them at scale,” Aleks Radovic-Moreno, Be Biopharma’s president and director, said in a phone interview. B cells, which play a lea...
16.11.2018	Lessons Learned: How to balance residency and a budding career in venture capital	Lessons Learned is STAT Plus’ column on careers in biomedicine. If you’re thinking of jumping from academics to industry/business or vice versa, join us for useful tips. And if you’ve recently jumped, send us a note: [email protected] Your ...
05.01.2016	Daily funding roundup - January 5, 2016	PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me...
22.07.2015	Daily funding roundup - July 22, 2015	Events.com has now raised a total of $17M; Darktrace landed $22.5M; Kinetic Social closed $17.5M Events.com has raised a new round of funding. The size of the round was undisclosed, but it was led by Arctaris and with participation from La ...
16.07.2012	Investors back female fertility treatment that may ‘reenergize’ eggs using stem cells	Based on infertility research by Jonathan Tilly at Massachusetts General Hospital, OvaScience’s lead program isolates a certain egg-producing stem cell found in the ovary and extracts the cells’ mitochondria, their main source of energy. As...
28.12.2010	Longwood Founders Management Closes Maiden Fund at $85M	Longwood Founders Management, LLC, a healthcare venture capital firm, closed its first fund at $85m. Investors in Longwood Founders Fund, L.P. include GlaxoSmithKline, Genzyme, and several institutional investors. Managed by partners Rich A...
-	Investors back female fertility treatment that may ‘reenergize’ eggs using stem cells	A company’s new technique to improve female infertility treatment based on the controversial idea that women aren’t in fact born with a finite number of eggs is getting the attention of investors — to the tune of more than $38 million raise...
-	Startup focused on B-cell therapies launched with $52M in Series A	After tackling two major research challenges, the founders of Be Biopharma are ready to announce their official launch along with a $52 million funding round. They are intent upon using the body’s B cells to treat a range of diseases. The S...

Longwood Fund

Portfolio 1

Mentions in press and media 21

Reviews 0